NSCLC
Conditions
Interventions
Bevacizumab with Osimertinib:Bevacizumab(15mg/kg,q3w) and Osimertinib(80mg,qd)
Sponsors
Taizhou First People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Volunteer to participate in clinical research; fully understand and know the research and sign the informed consent (ICF); willing to follow and have the ability to complete all trial procedures. 2. Aged >= 18 years when signing the ICF. 3. Advanced non-squamous non-small cell lung cancer patient with T790M mutation diagnosed by histology or cytology as resistant to first- and second-generation EGFR-TKI treatment. 4. At least one measurable lesion evaluated according to the requirements of RECIST Version 1.1. 5. Estimated survival time >= 12 weeks. 6. Good function of major organs.
Exclusion criteria
Exclusion criteria: 1. Active bleeding. Recently, pulmonary bleeding >= 1/2 teaspoon of bright red blood has occurred every day. 2. The imaging examination showed that there was a clear tumor invading the large blood vessels of the tumor. 3. Pregnancy or lactation. 4. Psychotropic drug abuse or drug abuse history. Subjects who agree not to drink alcohol during the study period can be included in the group. 5. According to the judgment of the investigator, the subject has other factors that may cause the study to be terminated midway.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Countries
China
Contacts
Public ContactLili Chen
Taizhou First People's Hospital
Outcome results
None listed